Precision BioSciences (NASDAQ: DTIL) — Company Overview, News & Financial Data
Precision BioSciences is a biotechnology firm specializing in genome editing therapies for cancer and genetic diseases.
Precision BioSciences
Precision BioSciences (NASDAQ:DTIL) is a biotechnology firm dedicated to improving lives through its proprietary genome editing platform, ARCUS. This innovative company is engaged in the development of novel therapeutics and solutions in the field of gene editing, with a keen focus on overcoming cancer and genetic diseases. Precision BioSciences is actively working on a range of projects including but not limited to, next-generation CAR T-cell therapies aimed at addressing unmet medical needs in oncology, and gene therapies to tackle rare genetic disorders. The company's objectives are rooted in leveraging its cutting-edge technology to create precise, targeted treatments that offer a significant advantage over existing therapies, ultimately striving to deliver revolutionary medical breakthroughs and improve patient outcomes.
Snapshot
Operations
Products and/or services of Precision BioSciences
- ARCUS gene editing platform, a technology for precise gene editing in healthcare, agriculture, and manufacturing.
- PBCAR0191, an allogeneic CAR T therapy targeting CD19 for B-cell malignancies.
- PBCAR20A, an off-the-shelf CAR T therapy aimed at treating Non-Hodgkin Lymphoma and other B-cell malignancies.
- PBCAR269A, designed for multiple myeloma treatment, leveraging an allogeneic CAR T approach.
- In Vivo Gene Correction using ARCUS for genetic diseases, focusing on liver-directed therapies.
- Allogeneic CAR T Cell Therapies for solid tumors, expanding the potential applications of their gene editing technology.
Precision BioSciences executive team
- Michael AmorosoPresident, CEO & Director
- John Alexander KellyChief Operating Officer
- Dario ScimecaChief Legal Officer & Secretary
- Jefferson J. SmithCo-Founder & Chief Research Officer
- Naresh TannaChief Financial Officer
- Mei BurrisVP of Finance & Chief Accounting Officer
- Cassie GorsuchChief Scientific Officer
- Juli BlancheChief People Officer
- Cindy AtwellChief Development Officer
- Neil LeatherburySenior VP and Head of Chemistry, Manufacturing & Controls
Latest news about Precision BioSciences
Precision BioSciences starts DMD gene trial
United StatesPrecision BioSciences posts first patient biopsy data proving Hepatitis B viral elimination
United StatesPrecision BioSciences swings to Q4 profit on Novartis milestone
United StatesPrecision BioSciences gains FDA fast track status for Duchenne gene editor
United States
Key financials
Reported results for Precision BioSciences, in USD.
- Market cap
- 191.8M
- Revenue (TTM)
- 45.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.3
- Dividend yield
- —
- Profit margin
- -117.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 34.3M | -52.1M | -45.7M | |
| 68.7M | -26.2M | 7.2M | |
| 48.7M | -43.7M | -61.3M | |
| 25.1M | -62.3M | -111.6M |